BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis

Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
Kaushal S GandhiDavid R Booth

Abstract

Multiple sclerosis (MS) is a complex autoimmune disease characterized by the destruction of the myelin sheath of neurons. Interferon beta (IFN-beta) is currently the major drug used to treat MS. Some patients fail to respond to this treatment, in some cases due to the development of neutralizing antibodies (NAb) to IFN-beta. We used microarray analysis and RT-PCR to measure gene expression in whole blood, 9-15 h postinjection, in patients with and without NAbs to IFN-beta. The canonical marker of biological response to IFN-beta, myxovirus resistance protein A, was upregulated in all NAb- patients while remaining unchanged in NAb+ patients. Genes functioning in immune response pathways were dominant in the set of differentially expressed genes: 73 immune response genes were identified as upregulated and 29 genes were identified as downregulated. B-cell activating factor (BAFF) is a strong candidate marker for biological and clinical response as well as for predisposition to NAb development. We demonstrate that it is responsive to IFN-beta in vitro and in vivo, and that its soluble form is elevated in serum from NAb- but not NAb+ patients. We conclude BAFF is a good biomarker for IFN-beta response, and requires further studies to...Continue Reading

References

Apr 1, 1997·European Journal of Immunogenetics : Official Journal of the British Society for Histocompatibility and Immunogenetics·G J StewartB H Bennetts
Jun 8, 1999·The Journal of Experimental Medicine·P SchneiderJ Tschopp
Dec 21, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·J ZhangT Zhou
Apr 5, 2001·Trends in Molecular Medicine·H LassmannC Lucchinetti
Oct 18, 2001·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·L DurelliM Bergui
Nov 21, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·B HuardL E French
May 9, 2002·Journal of the Neurological Sciences·Douglas R Jeffery
Jun 27, 2002·Neurology·A-M VallittuUNKNOWN Finnish Beta-Interferon Study Group
Dec 20, 2002·Nucleic Acids Research·Arvind RaghavanPaul R Bohjanen
Jan 15, 2003·Annals of the Rheumatic Diseases·X MarietteR Kimberly
Apr 23, 2003·Archives of Neurology·Maria Augusta Montenegro
Jun 5, 2003·Brain, Behavior and Evolution·Michael J WattJean M P Joss
Jul 31, 2003·Drugs·Peter Flachenecker, Peter Rieckmann
Oct 22, 2003·Lancet·Per Soelberg SorensenUNKNOWN Danish Multiple Sclerosis Study Group
Feb 24, 2004·International Immunology·Bertrand HuardLars E French
Jun 30, 2004·Journal of Neuroimmunology·Mathula ThangarajhPeter Hjelmström
May 3, 2005·Nature Reviews. Immunology·Leonidas C Platanias
Aug 2, 2005·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·H-P HartungH Schellekens
Aug 3, 2005·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·D R BoothUNKNOWN Southern MS Genetics Consortium
Oct 22, 2005·The Journal of Clinical Investigation·Thorsten M SeylerCornelia M Weyand
Dec 3, 2005·Multiple Sclerosis : Clinical and Laboratory Research·N ArbourJ P Antel
Dec 20, 2005·PLoS Genetics·Barbara E StrangerEmmanouil T Dermitzakis
Feb 8, 2006·Multiple Sclerosis : Clinical and Laboratory Research·F GilliA Bertolotto
Feb 14, 2006·Nature Reviews. Drug Discovery·Stacey R DillonAnne J Novak
Mar 15, 2006·Mayo Clinic Proceedings·Robert H Carter
Jun 13, 2006·Multiple Sclerosis : Clinical and Laboratory Research·E PortaccioM P Amato
Jul 31, 2007·The New England Journal of Medicine·UNKNOWN International Multiple Sclerosis Genetics ConsortiumStephen L Hauser
Jul 31, 2007·Nature Genetics·Simon G GregoryUNKNOWN Multiple Sclerosis Genetics Group
Oct 9, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Paolo A Muraro, Bibiana Bielekova
Oct 19, 2007·Nature·UNKNOWN International HapMap ConsortiumJohn Stewart

❮ Previous
Next ❯

Citations

Apr 9, 2013·Biomaterials·Tarun SaxenaRavi V Bellamkonda
Mar 21, 2012·Immunology and Cell Biology·Kerstin KieferAnn Marshak-Rothstein
Mar 30, 2013·Autoimmunity Reviews·Sonia Berrih-AkninRobert P Lisak
Jan 12, 2012·Autoimmune Diseases·Samia Ragheb, Robert P Lisak
Jul 16, 2010·Clinical Neurology and Neurosurgery·J J GraberS Dhib-Jalbut
Feb 13, 2010·Journal of Neuroimmunology·F PiazzaG Cavaletti
May 1, 2009·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Vinod RustgiG Mani Subramanian
Dec 17, 2014·Cytokine & Growth Factor Reviews·Martina SeveraEliana M Coccia
Sep 5, 2015·BioMed Research International·Michal RihacekLenka Zdrazilova-Dubska
Mar 17, 2009·Neurobiology of Disease·Clemens R Scherzer
Oct 25, 2011·Journal of Neuroimmunology·Ruth DobsonGavin Giovannoni
Nov 14, 2014·Multiple Sclerosis : Clinical and Laboratory Research·Sergio E BaranziniBruce Ac Cree
Mar 5, 2011·Multiple Sclerosis : Clinical and Laboratory Research·Samia RaghebRobert Lisak
Oct 10, 2012·Nature Reviews. Neurology·Markus KrumbholzEdgar Meinl
Nov 22, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Maria SjöstrandAlexander Espinosa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.